TIXiMED Announces Expansion of Program-Related Investment from the Helmsley Charitable Trust
TIXiMED, Inc., a clinical-stage pharmaceutical company developing innovative therapies for diabetes based on the breakthrough discovery of the role of TXNIP in disease progression, today announced the expansion of a program-related investment (PRI) made by The Leona M. and Harry B. Helmsley Charitable Trust in furtherance of their charitable purpose. The expanded PRI, in the form of a loan, provides TIXiMED with an additional $2.2 million to support the company's multiple ascending dose (MAD) Phase 1b clinical trial and long-term toxicology studies for TIX100, its investigational oral therapy designed to promote beta cell survival and function in individuals with Type 1 Diabetes (T1D).
TIXiMED Announces Promising Preclinical Data: Oral TIX100 Prevents Weight Regain After GLP-1 Cessation in Obesity Model
TIXiMED, Inc., a clinical-stage pharmaceutical company developing a novel oral therapy targeting thioredoxin-interacting protein (TXNIP) for diabetes and metabolic disorders, is pleased to highlight new research by investigators at the University of Alabama at Birmingham (UAB) Comprehensive Diabetes Center. The study demonstrates that its oral compound, TIX100, effectively prevents weight rebound following discontinuation of GLP-1 treatment in a mouse model of diet-induced obesity.
TIXiMED Announces Successful Completion of a Phase 1 Study of its Novel Oral Disease-Modifying Type 1 Diabetes Therapy
TIXiMED, Inc. (www.tiximed.com), a clinical-stage pharmaceutical company developing a novel disease-modifying oral therapy for type 1 diabetes (T1D), today announced the successful completion of the Phase 1 Single Ascending Dose (SAD) study for TIX100. This first human trial confirmed that TIX100 was safe and well-tolerated across all tested dose levels in healthy subjects. Additionally, post-hoc analysis revealed decreased postprandial blood glucose excursion and improved glucose homeostasis after a standardized liquid meal in the two highest dose cohorts, providing the first evidence of a biological TIX100 effect in humans.
TIXiMED Announces a $2.65M Program-Related Investment from the Helmsley Charitable Trust to Initiate Clinical Trials of Its Novel Oral Therapy for Beta Cell Survival and Function
TIXiMED, Inc. (https://tiximed.com), a clinical-stage pharmaceutical company based on the breakthrough discovery that TXNIP plays an important role in the development and progression of diabetes, has secured a program-related investment in the form of a $2.65M loan from The Leona M. and Harry B. Helmsley Charitable Trust. The non-dilutive funding will support the advancement of TIX100 into a first-in-human single ascending dose (SAD) study which will commence in January.
